

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	11079061
<b>Application Number:</b>	10594189
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7771
<b>Title of Invention:</b>	Recombinant Polypeptides of the Members of the Tnf Ligand Family and Use Thereof
<b>First Named Inventor/Applicant Name:</b>	Klaus Pfizenmaier
<b>Customer Number:</b>	27500
<b>Filer:</b>	Robert Bedgood/Patricia Munoz
<b>Filer Authorized By:</b>	Robert Bedgood
<b>Attorney Docket Number:</b>	040045-0357801-14619
<b>Receipt Date:</b>	29-SEP-2011
<b>Filing Date:</b>	13-JUL-2007
<b>Time Stamp:</b>	15:42:15
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$635
RAM confirmation Number	2199
Deposit Account	033975
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		roa0357801.PDF	3330454	yes	107
			7090ccf76c20bdbb142e26d5058bead0a0f92eed1		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Specification		2	6	
	Claims		7	9	
	Applicant Arguments/Remarks Made in an Amendment		10	18	
	Rule 130, 131 or 132 Affidavits		19	32	
	Response to Pre-Exam Sequence Notice		33	33	
	CRF Statement Paper and CRF are the same		34	34	
	Sequence Listing		35	84	
	Drawings-only black and white line drawings		85	105	
	Oath or Declaration filed		106	107	
	Warnings:				
Information:					
2	Sequence Listing (Text File)	TherapheresisSeqListing.txt	124478	no	0
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	30369	no	2
			0899e5146da31f7abab915a49325b1626231233b		
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.